- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02837991
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CDX-014 is an antibody-drug conjugate that binds to a protein called TIM-1, which is found on a high percentage of kidney cells that are clear or papillary and ovarian cancer cells that are clear cell.
The study will enroll patients with advanced or metastatic renal cell carcinoma and ovarian clear cell carcinoma to determine the safety and efficacy of CDX-014.
This study will include a Dose-Escalation Phase followed by a Cohort Expansion Phase
All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth Research Institute
-
-
California
-
Los Angeles, California, United States, 90033
- USC/Norris Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of advanced or metastatic clear cell or papillary renal cell carcinoma or histologically confirmed clear cell ovarian carcinoma.
- For RCC, at least two prior anticancer regimens (one must be a VEGF-targeted TKI), or are otherwise inappropriate candidates for all approved therapies. For OCCC, at least one line of prior therapy with a platinum and taxane regimen.
- Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
- Measureable (target) disease.
- Must have available tumor tissue for TIM-1 expression testing
- Life expectancy ≥ 3 months
- If of childbearing potential (male or female), agrees to use effective contraception during study treatment and for at least 6 months following last treatment dose.
Exclusion Criteria:
- Prior therapy containing MMAE
- Any prior cytotoxic chemotherapy regimen, including antibody drug conjugates for RCC or cytotoxic chemotherapy within 3 weeks of study treatment for OCCC
- Tyrosine kinase inhibitor (TKI) therapy within 2 weeks or at least 5 half-lives (whichever is longer) prior to planned start of study treatment.
- Monoclonal antibody therapy within 4 weeks prior to the planned start of study treatment.
- Radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).
- Major surgery or significant traumatic injury within 4 weeks prior to study entry.
- Use of other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study treatment.
- Concurrent severe and/or uncontrolled medical conditions (uncontrolled diabetes or infection), known infection with HIV, Hepatitis B or Hepatitis C.
- Brain metastases, unless previously treated and asymptomatic and not progressive for 2 months.
- Significant cardiovascular disease (including congestive heart failure).
- Other malignancy except for treated and cured basal or squamous cell skin cancer, cured in situ cancers, or other cancer from which the patient has been disease-free for ≥ 3 years.
- Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
- Chronic use of systemic corticosteroid above an accepted physiologic dose (5mg per day of prednisone or equivalent) within 7 days of enrollment except when used as premedication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CDX-014
During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable. The planned dose of CDX-014 depends on the cohort assigned at enrollment. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation - Determine Maximum Tolerated Dose (MTD)
Time Frame: Within 21 days after first dose.
|
Determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of CDX-014 (in mg/kg).
MTD will be defined as the highest dose-level where DLT (dose-limiting toxicity) occurs in less than 33% of treated patients.
|
Within 21 days after first dose.
|
Cohort Expansion - Assess Objective Response Rate (ORR)
Time Frame: Evaluated every 6-9 weeks following treatment initiation until treatment is discontinued or disease progression, up to 5 years.
|
Objective Response Rate (ORR) defined as the proportion of patients who achieve radiographic partial or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline.
|
Evaluated every 6-9 weeks following treatment initiation until treatment is discontinued or disease progression, up to 5 years.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms, Complex and Mixed
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Adenocarcinoma, Clear Cell
- Adenomyoepithelioma
Other Study ID Numbers
- CDX014-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Neoplasms
-
St. Petersburg State Pavlov Medical UniversitySaint Petersburg State University, RussiaCompleted
-
Philips HealthcareWithdrawnKidney TumorsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedKidney TumorUnited States
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Thomas MuellerUnknownKidney Neoplasms | Adult Polycystic Kidney Disease | Kidney DysfunctionSwitzerland
-
Intuitive SurgicalCompleted
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting
Clinical Trials on CDX-014
-
Huons Co., Ltd.UnknownPost Stroke Upper Limb SpasticityKorea, Republic of
-
MedRhythms, Inc.Alexion Pharmaceuticals, Inc.Not yet recruitingNeuromyelitis Optica Spectrum DisorderUnited States
-
Huons Co., Ltd.CompletedPost Stroke Upper Limb SpasticityKorea, Republic of
-
TargetCancer FoundationFoundation MedicineRecruitingCholangiocarcinoma | Cancer of Unknown Primary Site | Rare CancersUnited States
-
Fundación Universitaria CIEOUnknownCrowding of Anterior Mandibular TeethColombia
-
Flanders Medical Research ProgramCompleted
-
Washington University School of MedicineNational Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital; Celldex...TerminatedPancreatic Cancer | Pancreas Cancer | Cancer of the PancreasUnited States
-
C. R. BardCompletedPeripheral Artery DiseaseAustria, Belgium, France, Switzerland, Germany, Italy, Greece, Spain, United Kingdom, Portugal, Saudi Arabia
-
BIND TherapeuticsCompleted
-
BIND TherapeuticsCompletedCancer | Metastatic Cancer | Solid TumorsUnited States